Sign in

    Zachary Day

    Research Analyst at Canaccord Genuity

    Zachary Day most recently served as an Equity Research Analyst at Canaccord Genuity, specializing in healthcare and medical technology, where he covered companies such as TransMedics Group Inc. and AtriCure Inc., participating in earnings calls and industry research. During his tenure, Day demonstrated strong analytical acumen by asking targeted questions to company management, though specific quantitative performance metrics are not published. He began his finance career prior to Canaccord Genuity, later transitioning in 2024 to Excellere Partners, reflecting his progression from research analysis into private equity. Day’s credentials encompass experience in equity research and data analysis, and he has worked with other firms previously, building a foundation for capital markets and transaction diligence, though records of FINRA or licensing details are not publicly available.

    Zachary Day's questions to TransMedics Group (TMDX) leadership

    Zachary Day's questions to TransMedics Group (TMDX) leadership • Q2 2025

    Question

    Zachary Day, on for Bill Plozniak, inquired about Q2 market share trends by organ or donation type and the company's perspective on potential new competition in the liver market.

    Answer

    CEO Waleed Hassanein reiterated that the company does not provide intra-year share data but confirmed share gains continued in heart and liver. He stated he was unaware of specific new liver competitors but welcomes competition that aims to save more lives.

    Ask Fintool Equity Research AI

    Zachary Day's questions to AtriCure (ATRC) leadership

    Zachary Day's questions to AtriCure (ATRC) leadership • Q2 2025

    Question

    Zachary Day of Canaccord Genuity inquired about the impact of the LEAPS trial's enrollment completion on AtriClip utilization and how AtriCure manages discussions with electrophysiologists regarding PFA failures.

    Answer

    Michael Carrel, President, Director & CEO, clarified that the conclusion of LEAPS enrollment has a "zero impact" on revenue, as overall AtriClip adoption is rising due to increased market awareness. He described conversations with EPs about PFA as collaborative and scientific, positioning AtriCure's epicardial ablation as an additive therapy for complex patients rather than a direct competitor.

    Ask Fintool Equity Research AI